PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Core Viewpoint - The Schall Law Firm is investigating Pliant Therapeutics, Inc. for potential violations of securities laws following a significant drop in share price after the company paused a clinical trial [1][2]. Group 1: Investigation Details - The investigation centers on whether Pliant issued false or misleading statements or failed to disclose important information to investors [2]. - Pliant announced a voluntary pause in enrollment and dosing for the BEACON-IPF Phase 2b trial of bexotegrast due to recommendations from the independent Data Safety Monitoring Board [2]. Group 2: Market Impact - Following the announcement of the trial pause, Pliant's shares experienced a dramatic decline of 60.59% on February 10, 2025 [2].